CytomX’s EpCAM Push Faces Scrutiny — Analysts Lower Rating Pending Proof
CytomX refocuses on EpCAM-targeted Probody therapy, but analysts downgrade the stock pending clinical proof of durable efficacy, manageable safety and clearer valuation.
Seeking Alpha
2 min read
Biotechnology
Stocks
Market Analysis